4.8 Article

Structure and Cancer Immunotherapy of the B7 Family Member B7x

Journal

CELL REPORTS
Volume 9, Issue 3, Pages 1089-1098

Publisher

CELL PRESS
DOI: 10.1016/j.celrep.2014.09.053

Keywords

-

Categories

Funding

  1. NIH [R01CA175495, GM094662, GM094665, UL1TR000086, F31CA183493, T32GM007288]
  2. DOD [PC131008]
  3. Albert Einstein Cancer Center [P30CA013330]
  4. Diabetes Research Center [P60DK020541]
  5. Center for AIDS Research [AI51519]
  6. Institute for Aging Research [P30AG038072]

Ask authors/readers for more resources

B7x (B7-H4 or B7S1) is a member of the B7 family that can inhibit T cell function. B7x protein is absent in most normal human tissues and immune cells, but it is overexpressed in human cancers and often correlates with negative clinical outcome. The expression pattern and function of B7x suggest that it may be a potent immunosuppressive pathway in human cancers. Here, we determined the crystal structure of the human B7x immunoglobulin variable (IgV) domain at 1.59 angstrom resolution and mapped the epitopes recognized by monoclonal antibodies. We developed an in vivo system to screen therapeutic monoclonal antibodies against B7x and found that the clone 1H3 significantly inhibited growth of B7x-expressing tumors in vivo via multiple mechanisms. Furthermore, the surviving mice given 1H3 treatment were resistant to tumor rechallenge. Our data suggest that targeting B7x on tumors is a promising cancer immunotherapy and humanized 1H3 may be efficacious for immunotherapy of human cancers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available